Vertex Pharmaceuticals (VRTX) EBITDA Margin (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly EBITDA Margin of 38.1% for Q1 2026, up 1536.0% year-over-year from 2.33% in Q1 2025, and up 0.8% quarter-over-quarter from 37.8% in Q4 2025.
Powered by 
Analysis
Vertex Pharmaceuticals (VRTX) EBITDA Margin (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' EBITDA Margin history runs 18 years deep, the most recent figure standing at 38.1% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 1536.0% year-over-year to 38.1%; the TTM figure through Mar 2026 stood at 38.31% (up 4500.0% YoY), while the FY2025 annual figure was 34.77%, up 3689.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 38.1%, up from 37.8% in the prior quarter.
- The five-year high for EBITDA Margin was 50.37% in Q2 2022, with the low at 132.85% in Q2 2024.
- The 5-year median for EBITDA Margin is 39.26% (2023), against an average of 29.95%.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin sank 17402 bps in 2024, then soared 17168 bps in 2025.
- Vertex Pharmaceuticals' EBITDA Margin stood at 44.88% in 2022, then decreased by 13 bps to 39.26% in 2023, then decreased by 10 bps to 35.23% in 2024, then rose by 7 bps to 37.8% in 2025, then grew by 1 bps to 38.1% in 2026.
- Business Quant data shows VRTX's EBITDA Margin at 38.1% in Q1 2026, 37.8% in Q4 2025, and 38.56% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - | 19.75% |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn | -0.36% |
| 10 | Incyte | 25.60 Bn | 21.07 Bn | 1.57 Bn | 41.69% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 37.40% |
| Mar 31, 2026 | 38.10% |
| Dec 31, 2025 | 37.80% |
| Sep 30, 2025 | 38.56% |
| Jun 30, 2025 | 38.83% |
| Mar 31, 2025 | 22.75% |
| Dec 31, 2024 | 35.23% |
| Sep 30, 2024 | 40.27% |
| Jun 30, 2024 | -132.85% |
| Mar 31, 2024 | 42.35% |
| Dec 31, 2023 | 39.26% |
| Sep 30, 2023 | 41.80% |
| Jun 30, 2023 | 41.17% |
| Mar 31, 2023 | 32.80% |
| Dec 31, 2022 | 44.88% |
| Sep 30, 2022 | 48.27% |
| Jun 30, 2022 | 50.37% |
| Mar 31, 2022 | 49.63% |
| Dec 31, 2021 | 42.35% |
| Sep 30, 2021 | 53.15% |